Streetbeat News

Revenues

TSLA

WKSP

The article discusses the mixed performance of the EV market globally. While Tesla and traditional automakers like General Motors and Ford are experiencing slowdowns and challenges in the U.S. and Europe, China's EV market is booming. Worksport Ltd. is highlighted for its impressive revenue growth and upcoming innovative products.

Portfolio Pulse from Upwallstreet

August 15, 2024 | 6:54 pm

HCM

Hutchmed's U.S. sales of its cancer drug Fruzaqla surged nearly 53% in Q2, but net profits fell 85% due to a high base effect from a previous licensing deal. The company plans to focus on innovative drugs and may divest its traditional Chinese medicine business.

Portfolio Pulse from The Bamboo Works

August 15, 2024 | 6:52 pm

RDW

Redwire shares are trading higher after the company raised its FY24 revenue guidance above estimates and announced the acquisition of Hera Systems.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 6:40 pm

BABA

Alibaba Group Holding Limited (NYSE:BABA) reported its fiscal first-quarter 2024 earnings, showing mixed results. Revenue increased by 4% year-over-year to $33.47 billion, missing analysts' expectations of $34.81 billion. However, adjusted earnings per ADS beat estimates, coming in at $2.26 versus the expected $2.13. Various business segments showed mixed performance, with international commerce and cloud services showing significant growth. Alibaba's shares rose by 0.38% to $79.17 following the report.

Portfolio Pulse from Vaishali Prayag

August 15, 2024 | 6:10 pm

THQQF

Embracer Group AB (OTC:THQQF) reported a 24% decline in net sales for Q1 2024, amounting to $754 million. The company experienced a significant drop in PC and console gaming revenue, while tabletop games remained the largest revenue generator. Embracer plans to split into three publicly listed entities, with Asmodee expected to be listed on Nasdaq Stockholm by the end of the year.

Portfolio Pulse from Franca Quarneti

August 15, 2024 | 6:01 pm

IGMS

Four analysts have provided varied opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, with ratings ranging from somewhat bullish to indifferent. The average 12-month price target has increased by 9.52% to $17.25. Key analysts have either raised or maintained their ratings, with price targets ranging from $12.00 to $25.00. Despite challenges in revenue growth and below-average ROE and ROA, the company maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 6:01 pm

ASO

AYRO

BIRK

BLD

BYON

COOK

CPRI

DKNG

ECX

EWCZ

FEBO

FTEL

HSAI

KRUS

NCLH

NWL

PTON

RENT

RMBL

RVLV

SVMH

SWIM

TCTM

VIK

VIOT

VSCO

WRBY

YETI

Shares of companies within the broader consumer discretionary sector are trading higher following strong economic data that helps ease recession concerns.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:46 pm

Sea Limited (NYSE:SE) has significantly outperformed the market over the past 5 years, delivering an average annual return of 19.2%. An initial investment of $1000 in SE stock 5 years ago would now be worth $2,200. The company's current market capitalization stands at $45.61 billion.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 5:32 pm

ARKR

CBRL

CCL

CMG

CNTY

CUK

CZR

DIN

MGM

RCL

SHAK

YUMC

Shares of hotel, restaurant, and leisure companies are trading higher following strong economic data that helps ease recession concerns.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:31 pm

CVNA

HTZ

KMX

PAG

SAH

STLA

VVV

Shares of auto and auto-related stocks are trading higher following a rise in July auto sales.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:30 pm